Related Experiment Video
Updated: Sep 15, 2025

Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
[GLP1 receptor agonist drug treatments and adult obesity]
Claire Carette1, Aurélie Phan1, Sébastien Czernichow1
1Service de nutrition, Hôpital européen Georges-Pompidou, AP-HP, Centre spécialisé obésité Île-de-France Ouest, 20 rue Leblanc, Paris, France; Université Paris Cité, 12 rue de l'École de Médecine, 75006 Paris, France.
Abstract:
Obesity is a chronic disease with multiple causes and serious complications. Treatments include lifestyle modifications and, for severe cases, medication. Today, molecules such as liraglutide and semaglutide are showing promising results in terms of weight loss and even cardiovascular benefits (for the latter), although reimbursement is limited in France. The dual agonist of glucagon-like peptide 1 and glucose-dependent insulinotropic peptide receptors (tirzepatide) also offers encouraging prospects. Research is continuing with bi- and tri-agonists to improve the management of obesity.
Related Concept Videos
Glucagon-like Receptor Agonists
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
Oral Hypoglycemic Agents: Glinides
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...

